References
Avril MF, Aamdal S, Grob JJ, et al (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22:1118–1125
Eskelin S, Pyrhönen S, Hahka-Kemppinen M, Tuomaala S (2003) A prognostic model and staging for metastatic uveal melanoma. Cancer 97:465–475
Flaherty LE, Liu PY, Unger J, Sondak VK (1997) Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma. Am J Clin Oncol 20:600–604
Pföhler C, Cree IA, Ugurel S, Kuwert C, et al (2003) Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study. Anticancer Drugs 14:337–340
Serrone L, Zeuli M, Sega FM, Cognetti F (2000) Dacarbacine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 19:21–34
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Terheyden, P., Bröcker, EB. & Becker, J.C. Reply concerning “Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma” by Terheyden et al. (2004). J Cancer Res Clin Oncol 131, 331 (2005). https://doi.org/10.1007/s00432-004-0631-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-004-0631-2